DermTech, Inc. (DMTK): Price and Financial Metrics
DMTK Stock Summary
- For DMTK, its debt to operating expenses ratio is greater than that reported by just 4.66% of US equities we're observing.
- DMTK's price/sales ratio is 183.19; that's higher than the P/S ratio of 97.61% of US stocks.
- The volatility of DermTech Inc's share price is greater than that of 97.27% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to DermTech Inc are NVRO, CYRX, EKSO, DADA, and BIOL.
- Visit DMTK's SEC page to see the company's official filings. To visit the company's web site, go to www.dermtech.com.
DMTK Stock Price Chart Interactive Chart >
DMTK Price/Volume Stats
| Current price | $34.50 | 52-week high | $84.49 |
| Prev. close | $37.49 | 52-week low | $9.64 |
| Day low | $34.25 | Volume | 786,970 |
| Day high | $37.40 | Avg. volume | 1,502,830 |
| 50-day MA | $56.23 | Dividend yield | N/A |
| 200-day MA | $27.02 | Market Cap | 992.08M |
DermTech, Inc. (DMTK) Company Bio
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Latest DMTK News From Around the Web
Below are the latest news stories about DermTech Inc that investors may wish to consider to help them evaluate DMTK as an investment opportunity.
OptumInsight Study Describes Cost Savings of DermTech’s Pigmented Lesion Assay in the Management of MelanomaDermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results from its second economic study of the Pigmented Lesion Assay ("PLA"), a non-invasive genomic test that enhances early melanoma detection. The PLA increases detection of lesions at high risk for melanoma while reducing unnecessary surgical procedures relative to the existing diagnostic pathway of visual assessment and histopathology ("VAH"). OptumInsight ("Optum") developed an actuarial model to evaluate the economic impact of inserting the PLA into the VAH pathway for pigmented skin lesions clinically suspicious of melanoma. |
DermTech Inc: A Compelling Growth Story With UpsidePhoto by Anastasiia Stiahailo/iStock via Getty Images Skin cancer is the most common form of cancer in the United States. There are more cases of skin cancer diagnosed each year than all other cancers combined. But like many aspects of the healthcare system, the way we go about diagnosing skin... |
Should Investors Be Worried About DermTech's Decline From Its 52-Week Highs?DermTech (NASDAQ: DMTK) is trading well off its 52-week high of $84.49 per share while investors try to figure out how to value the prospects of the dermatology company. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights talk about what the company is doing to grow sales of its melanoma test and why the recent decline shouldn't be a big concern for long-term investors. Brian Orelli: Max asks, any info or thoughts on DermTech following and its prospects, bought it a high valuation and think they are creating fantastic products, so the sell-off is a little disconcerting. |
Could DermTech Be a Millionaire-Maker Stock?DermTech (NASDAQ: DMTK) has the potential to be a truly disruptive genomics company, one that could change dermatology entirely. Skin cancers are the most prevalent form of cancer, affecting one in five Americans by the age of 70, according to the Skin Cancer Foundation. The most common forms of skin cancer are basil cell carcinoma and squamous cell carcinoma, but the most deadly is melanoma, according to a American Cancer Society report, which estimated that of the more than 100,000 people who were diagnosed with melanomas in the United States in 2020, 6,850 of them died from the disease. |
Should You Invest in Humacyte Before the SPAC Merger?Investors can get an early stake in Humacyte, the biotech developing human acellular vessels, by buying shares in Alpha Healthcare Acquisition Corp. (NASDAQ: AHAC), the special acquisition company (SPAC) that plans to merge with Humacyte. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com Contributors Brian Orelli and Keith Speights discuss Humacyte's prospects and whether it's more appropriate for a portfolio or a watch list. Brian Orelli: Moving onto Humacyte, the company is going public through a merger with a special acquisition company (SPAC) called Alpha Healthcare Acquisition. |
DMTK Price Returns
| 1-mo | -40.10% |
| 3-mo | -21.14% |
| 6-mo | 165.38% |
| 1-year | 176.00% |
| 3-year | 73.37% |
| 5-year | N/A |
| YTD | 6.35% |
| 2020 | 161.61% |
| 2019 | -39.28% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...